{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'with sites until after study completion. If clinical circumstances arise for which AT activity', 'levels are required to guide patient care, local laboratory assessments may be drawn.', '7.3.1.', 'Antithrombin (AT) Activity', 'AT activity level will be assessed according to the schedule of assessments (Table 1); samples', 'will be collected within 4 hours prior to dosing. Antithrombin levels will be determined by', 'validated assay. Antithrombin protein may be measured in a subset of plasma samples for', 'correlation. Results will be collected and interpreted centrally.', 'In the fitusiran treatment arm patients who do not enroll in the extension study, following final', 'fitusiran dose, AT activity level will be monitored at monthly intervals until returning to an', 'activity level of approximately 60% (per the central laboratory) or per Investigator discretion in', 'consultation with the study Medical Monitor.', '7.3.2.', 'Thrombin Generation', 'Thrombin generation will be assessed according to the Schedule of Assessments (Table 1) using', 'a functional assay per the Laboratory Manual, and will be collected and interpreted centrally.', '7.3.3.', 'Exploratory Analyses', 'Except where prohibited by local or national regulations, in consented patients, plasma, serum,', 'and urine samples may be archived and used for analyses of exploratory biomarkers related to', 'the metabolic profiling or effects of fitusiran and for the development of modified thrombin', 'generation assays, and may also be archived for use in other exploratory analyses related to', 'hemophilia and its complications.', 'In addition, where permitted in consented patients, serum samples may be used for analysis of', 'circulating RNA, including the assessment of cleaved AT RNA, and a sample of DNA may be', 'obtained and archived to permit potential confirmation of hemophilia mutation or genotyping of', 'hemophilia modifier genes or genes that may modify the effects of fitusiran.', '7.4.', 'Pharmacokinetic Assessments', 'Blood samples will be collected for assessment of PK including metabolites (as necessary) in all', 'fitusiran arm patients according to the collection schedule presented in Table 7, on the days', 'specified in the Schedule of Assessments (Table 1).', 'Blood must be aliquoted and processed as plasma for PK analysis. All plasma concentration data', '(Table 7 and Table 8) will be summarized and analyzed using a population PK approach.', 'In addition, plasma PK (Table 8, which includes all time points in Table 7) will be evaluated in', 'East Asian patients in the fitusiran arm at East Asian sites (defined as patients from sites in', 'China, Japan, South Korea, and Taiwan), and there will be pooled urine collection for urine PK', 'analysis also in these patients (Table 9).', 'The concentration of fitusiran will be determined using a validated assay. Full details regarding', 'the processing, shipping, and analysis of the samples will be provided in the Laboratory Manual.', 'Property of the Sanofi Group - strictly confidential', '55']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '7.5.', 'Safety Assessments', 'The assessment of safety during the course of the study will consist of the surveillance and', 'recording of AEs including SAEs, recording of concomitant medication and measurements of', 'vital signs, weight and height, physical examinations, ECG findings, and laboratory tests.', 'Safety data will be periodically reviewed over the course of the study by the DMC as described', 'in Section 4.6.', '7.5.1.', 'Vital Signs', 'Vital signs will be measured as specified in the Schedule of Assessments (Table 1), and will', 'include blood pressure, heart rate, body temperature, and respiratory rate. Vital signs will be', 'measured predose in the seated or supine position, after the patient has rested comfortably for', '10 minutes.', 'Body temperature in degrees Celsius will be obtained via oral, tympanic, or axillary methods.', 'Heart rate will be counted for a full minute and recorded in beats per minute, and respiration rate', 'will be counted for a full minute and recorded in breaths per minute.', 'For the safety of the patient, additional vital sign assessments may be added at the discretion of', 'the Investigator.', 'Vital signs results will be recorded in the eCRF.', '7.5.2.', 'Weight and Height', 'Height will be measured in centimeters. Body weight will be measured in kilograms. Height', 'and body weight measurements will be collected as specified in the Schedule of Assessments', '(Table 1) and will be recorded in the eCRF.', '7.5.3.', 'Physical Examination', 'Full and directed physical examinations will be conducted as specified in the Schedule of', 'Assessments (Table 1); if a physical examination is scheduled for a dosing visit, it should be', 'conducted prior to dosing.', 'Full physical examinations will include the examination of the following: general appearance,', 'head, eyes, ears, nose and throat; respiratory, cardiovascular, gastrointestinal, musculoskeletal', 'and dermatological systems; thyroid, lymph nodes, and neurological status.', 'Directed physical examinations will include the examination of the following systems with', 'attention to evaluation for signs and symptoms of thrombosis, bleeding, and arthropathy:', 'neurologic, chest/respiratory, heart/cardiovascular, dermatological/skin, gastrointestinal/liver,', 'and musculoskeletal/extremities Other organ systems may be evaluated as indicated by patient', 'symptoms. In patients undergoing a surgical procedure, a directed physical examination will', 'also be performed as specified in the Perioperative Schedule of Assessments (Table 10).', 'Physical examination notes regarding any observed abnormalities will be recorded on the eCRF.', 'Property of the Sanofi Group - strictly confidential', '56']\n\n###\n\n", "completion": "END"}